Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Influence of Sarcopenia on the Course of the Diseases

Key facts

Where
Mainz, GermanySee the site

Where in Germany

  • Universitätsmedizin MainzMainz, GermanyContact: Wolfgang Maximilian Kremer WMK Kremer, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Universitatsmedizin Mainz - 1. Medizinische Klinik
Trial code
NCT06829290
Record updated
17 February 2025
Original description
Frailty is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as liver cirrhosis or pancreatitis. Sarcopenia, a form of frailty, is defined as a loss of muscle quantity, quality and function. Currently, complex methods such as CT or bioimpedance measurement are available. However, simpler techniques such as ultrasound-based measurement could be alternatives, but still require further validation. In addition, serological muscle markers could support and simplify diagnostics.Read full original descriptionShow less

Influence of Sarcopenia on the Course of the Diseases - Measured Using Ultrasound and Biochemical Markers

Frailty is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as liver cirrhosis or pancreatitis. Sarcopenia, a form of frailty, is defined as a loss of muscle quantity, quality and function. Currently, complex methods such as CT or bioimpedance measurement are available. However, simpler techniques such as ultrasound-based measurement could be alternatives, but still require further validation. In addition, serological muscle markers could support and simplify diagnostics.

The aim of this project is to be able to estimate the prognosis of patients at an early stage by measuring sarcopenia using ultrasound and biomarkers.

Inclusion: oncological patient in the field of gastrointestinal tumors; patients with liver cirrhosis; patients attending the intensive care unit.

Exclusion: patients with congenital muscle diseases; patients incapable of consenting.

ClinicalTrials.gov NCT06829290